3Q PREVIEW: Merck, Novartis, Pfizer, Sanofi and Gilead
This article was originally published in Scrip
Executive Summary
Analysts have been expecting a reasonably quiet third quarter earnings seasons ahead of catalysts in 4Q. However, the relative peace was shattered when GlaxoSmithKline took the occasion of its 3Q report this week to announce a new £1bn restructuring program alongside its beleaguered financial results and revealed its intention to float part of its HIV venture ViiV Healthcare (scripintelligence.com, 23 October 2014).
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.